Cyngn Announces Closing of $5.0 Million Firm Commitment Public Offering of Common Stock April 25, 2024
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic April 25, 2024